Thursday night the biotech company offloaded the product, and its mesenchymal stem cell platform in regenerative medicine, to Australia's Mesoblast for $50 million in near-term cash and stock and up to $50 million more in milestones.
Boston University and London-based MRC Technology are partnering to develop an antibody for use in treatment of inflammatory diseases and ischemic reperfusion injury, tissue damage caused by a sudden loss of blood.
Two years after Takeda acquired Nycomed, it's opted to punt a troubled partnership it inherited with Immunomedics on an anti-CD20 antibody pact struck 5 years ago for up to $620 million.
Medtronic will link with Apollo Hospitals Enterprise--one of India's largest healthcare providers--to develop a portable kidney dialysis system. The project represents the Minnesota device giant's first foray into hemodialysis and yet another diversification move for the company.
Rounding the bend on a likely approval for its hepatitis C drug simeprevir, J&J has acquired an NS5A replication complex inhibitor from GlaxoSmithKline to add to its combination approach to the disease.
Researchers at The Cancer Institute at NYU Langone Medical Center are heading up a $6.25 million, 5-year research initiative to develop new therapies and increase the cure rate for children and young adults with acute lymphoblastic cancer, the most common form of childhood cancer.
AMRI has signed a long-term contract with the U.K.'s defense department, agreeing to take an investigational drug to Phase I with a chance to re-up once there.
In yet another tie-up with a biotech upstart, Celgene has committed $35 million to PharmAkea Therapeutics, signing a three-deal to collaborate on cancer and fibrosis development.
Biotech billionaire Randal "RJ" Kirk's synthetic biology company Intrexon has announced plans to partner with India's Sun Pharmaceutical on a pipeline of new drugs for ocular diseases, starting with dry age-related macular degeneration.
Small New Jersey delivery specialist Enteris BioPharma, which only just opened its doors in April of this year, entered a licensing agreement for an undisclosed amount with Dutch Nordic Bioscience for Enteris's oral-delivery tech for peptides and small molecules.